Related Experiment Videos
Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate
P Koivisto1, T Visakorpi, O P Kallioniemi
1Laboratory of Cancer Genetics, University of Tampere, Finland.
Abstract:
Since the development and growth of the prostate cancer is highly dependent on androgens, androgen deprivation therapy continues to be the treatment of choice for patients with advanced prostate cancer. The therapy is very effective, but responses are often short-lived. We describe here a novel molecular mechanism that may explain why prostate cancer cells become resistant to hormonal therapy. Amplification of the androgen receptor (AR) gene was found to be selected for during androgen deprivation therapy in 23% of prostate cancer patients who experienced local tumor recurrence. Amplification leads to increased expression of the AR gene, which enables the cancer cells to more effectively utilize the residual low levels of androgens for sustaining cell growth. Discovery of AR amplification as a possible molecular mechanism of therapy resistance in prostate cancer should prove useful for development of more effective endocrine therapy regimens as well as diagnostic and predictive tests for therapy failure.
Insights
Androgen deprivation therapy resistance in prostate cancer may stem from androgen receptor (AR) gene amplification. This allows cancer cells to use low androgen levels for growth, leading to treatment failure.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer.
- While effective, ADT responses are often temporary, with cancer eventually becoming resistant.
- Understanding resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To identify novel molecular mechanisms driving prostate cancer resistance to hormonal therapy.
- To investigate the role of androgen receptor (AR) gene alterations in treatment failure.
Main Methods:
- Analysis of prostate cancer patients undergoing ADT with local tumor recurrence.
- Investigating gene amplification events, specifically for the androgen receptor (AR) gene.
Main Results:
- Androgen receptor (AR) gene amplification was identified in 23% of patients with recurrent prostate cancer after ADT.
- AR gene amplification correlates with increased AR gene expression.
- This amplification enables cancer cells to utilize low androgen levels for sustained growth.
Conclusions:
- AR gene amplification represents a key molecular mechanism for prostate cancer therapy resistance.
- This finding can inform the development of new endocrine therapies.
- It may also lead to improved diagnostic and predictive tests for therapy failure.